Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Validation of Predictors of OAC Initiation Using EMR Data

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Dabigatran etexilate
Drug: Warfarin

First Posted Date: 2016-12-30

Last Posted Date: 2019-03-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 140187

Registration Number: NCT03006341

Locations: 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Spiolto® Respimat®

First Posted Date: 2016-12-28

Last Posted Date: 2019-09-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 306

Registration Number: NCT03003494

Locations: 🇮🇹
Ospedale Generale Regionale "Miulli", Acquaviva Delle Fonti (BA), Italy
🇮🇹
Azienda Ospedaliera G. Rummo, Benevento, Italy
🇮🇹
Casa di cura Mons. Calaciura, Biancavilla, Italy

and more 25 locations

To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BI 730357
Drug: Placebo

First Posted Date: 2016-12-28

Last Posted Date: 2023-08-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 84

Registration Number: NCT03004404

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Ibuprofen/Caffeine Lower Back or Neck Pain Study

Phase 3

Completed

Conditions: Back Pain
Neck Pain

Interventions: Drug: ibuprofen
Drug: placebo
Drug: caffeine

First Posted Date: 2016-12-26

Last Posted Date: 2019-06-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 635

Registration Number: NCT03003000

Locations: 🇩🇪
Praxis Dr. Steinebach, Essen, Essen, Germany
🇩🇪
Praxis Dr. Pabst, Gilching, Gilching, Germany
🇩🇪
Praxis Dr. Klein, Künzing, Künzing, Germany

and more 15 locations

Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BI 1467335 (Treatment C)
Drug: BI 1467335 (Treatment A)
Drug: BI 1467335 (Treatment B)

First Posted Date: 2016-12-21

Last Posted Date: 2021-06-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02999191

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Phase 3

Completed

Conditions: Lung Diseases, Interstitial

Interventions: Drug: Placebo
Drug: Nintedanib

First Posted Date: 2016-12-21

Last Posted Date: 2020-05-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 663

Registration Number: NCT02999178

Locations: 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇧🇪
ULB Hopital Erasme, Bruxelles, Belgium

and more 149 locations

Treatment Pattern of Oral Anticoagulants (OAC) in Japan

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2016-12-06

Last Posted Date: 2018-09-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48696

Registration Number: NCT02982863

Locations: 🇯🇵
NISED Center, Tokyo, Shinagawa, Japan

Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Spesolimab

First Posted Date: 2016-12-01

Last Posted Date: 2023-08-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT02978690

Locations: 🇲🇾
Hospital Sultanah Aminah, Johor Bahru, Malaysia
🇫🇷
HOP Saint-Louis, Paris, France
🇰🇷
Pusan National Univ. Hosp, Busan, Korea, Republic of

and more 3 locations

BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: BI 443651
Drug: Placebo

First Posted Date: 2016-11-29

Last Posted Date: 2019-11-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02976519

Locations: 🇬🇧
The Medicines Evaluation Unit, Manchester, United Kingdom
🇩🇪
Lungenärztliche Praxis, München-Pasing, Germany
🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany

and more 2 locations

Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium
Drug: Olodaterol

First Posted Date: 2016-11-21

Last Posted Date: 2019-03-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02969317

Locations: 🇨🇳
West China Hospital, Chengdu, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy